Cargando…
Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
While patients with resectable pancreatic ductal adenocarcinoma (PDAC) show improved survival compared to their non-resectable counterparts, survival remains low owing to occult metastatic disease and treatment resistance. Liquid biopsy based on circulating tumor cells (CTCs) and cell-free DNA (cfDN...
Autores principales: | Dopico, Pablo J., Le, Minh-Chau N., Burgess, Benjamin, Yang, Zhijie, Zhao, Yu, Wang, Youxiang, George, Thomas J., Fan, Z. Hugh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028387/ https://www.ncbi.nlm.nih.gov/pubmed/35448266 http://dx.doi.org/10.3390/bios12040206 |
Ejemplares similares
-
Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015) -
Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017) -
Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma
por: McGowan, Ryan, et al.
Publicado: (2022) -
Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection
por: Gablo, Natalia, et al.
Publicado: (2020) -
Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients
por: Hansen, Frederik J., et al.
Publicado: (2023)